ArticlesChemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data*,
Introduction
About 400 000 head and neck squamous-cell carcinomas are diagnosed worldwide annually,1 most of which are locally advanced at presentation.2 Surgery and/or radiotherapy are the mainstay of locoregional treatment,3 and are often followed by chemotherapy especially in locally advanced disease. Chemotherapy induces tumour responses, but is toxic and costly. It is therefore important to know whether its addition leads to clinical benefits. Over 70 randomised trials in more than 12 000 patients have compared locoregional treatment plus chemotherapy versus the logoregional treatment alone. However, most of these trials were too small to detect even a moderate effect on survival. Yet chemotherapy is routinely used in locally advanced disease.4 In the absence of a large (over 1000-2000 patients) randomised trial, the most reliable way to evaluate chemotherapy is to do a meta-analysis based on updated individual data. The Meta-Analysis of Chemotherapy on Head and Neck Cancer (MACH-NC) collaborative group reports such an overview here.
Section snippets
Methods
The methods were specified in a protocol (available on request from JPP).
Results
The trials we included are detailed in The Lancet's website with a short description of the excluded trials (http://www.thelancet.com) The trials' references and a sensitivity analyses can also be found there.
Larynx preservation
The third meta-analysis included patients with locally advanced laryngeal or hypopharyngeal carcinomas and compared radical surgery plus radiotherapy with a neoadjuvant combination of cisplatin and fluorouracil followed by radiotherapy in responders or radical surgery plus radiotherapy in non-responders. The three trials identified (table 3) included 602 patients, with a median follow-up of 5·7 years.
The pooled hazard ratio (1·19, 0·97–1·46, figure 6) showed a non-significant trend (p=0·1) in
Discussion
In the first meta-analysis on the addition of chemotherapy to locoregional treatment, the most important result was a small, but statistically significant, overall benefit in survival with chemotherapy (the absolute benefit at 2 and 5 years was 4%). This size of effect of chemotherapy in head and neck squamous-cell carcinoma is similar to that observed in non-small-cell lung cancer.11 Prespecified analyses of the timing of chemotherapy suggested no significant benefit of adjuvant or neoadjuvant
References (13)
- et al.
A note on quantifying follow-up in studies of failure time.
Controlled Clin Trials
(1996) - et al.
Beta blockade during and after myocardial infarction: an overview of randomised clinical trials.
Prog Cardiovasc Dis
(1985) - et al.
Meta-analysis of the literature or individual patient data: is there a difference?
Lancet
(1993) - et al.
Randomized trial of induction chemotherapy in larynx carcinoma.
Eur J Cancer
(1998) - et al.
Meta-analyses in head and neck squamous cell carcinoma: what is the role of chemotherapy?
Hematol Oncol Clin North Am
(1999) - et al.
Cancer incidence in five continents
Lyon: IARC
(1992)
Cited by (0)
- *
Collaborators listed at end of paper
References 70 and 71 (see website) have WR Bezwoda as a co-author. One of Dr Bezwoda's other studies has recently beed audited negatively. References 70 and 71 contributed 58 and 27 patients to the meta-analysis. The authors have informed us that the overall hazard ratio in the meta-analysis is the same with or without these data. In the concomitant group, the hazard ratio changes from 0·81 to 0·83, but is anyway not statistically significant—Ed.